8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________

FORM 8-K

__________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 10, 2022

__________________________________________________

ABCELLERA BIOLOGICS INC.

(Exact name of registrant as specified in its charter)

__________________________________________________

British Columbia	001-39781	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

2215 Yukon Street Vancouver, BC	V5Y 0A1
(Address of registrant’s principal executive office)	(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common shares	ABCL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02    Results of Operations and Financial Condition

On May 10, 2022, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the quarter ended March 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01    Regulation FD Disclosure

In connection with its earnings call on May 10, 2022, to discuss its results for the quarter ended March 31, 2022, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01    Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued by AbCellera Biologics Inc. on May 10, 2022.
99.2	Corporate presentation.
104	Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 10, 2022	ABCELLERA BIOLOGICS INC.
	By:	/s/ Carl L. G. Hansen
		Carl L. G. Hansen, Ph.D.
		Chief Executive Officer and Director (Principal Executive Officer)

EX-99.1

Exhibit 99.1

NEWS RELEASE

AbCellera Reports Q1 2022 Business Results

05/10/2022

 

● Total revenue of $317 million, compared to $203 million in Q1 2021

● Six program starts in the quarter bringing cumulative total to 84, up 56% from Q1 2021

● Net earnings of $0.59 per share on a basic and $0.54 on a diluted basis compared to $0.43 (basic) and $0.37 (diluted) per share in Q1 2021

VANCOUVER, British Columbia, May 10, 2022 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“We entered 2022 with strong momentum that we leveraged to start new drug discovery programs and demonstrate the power of our platform by discovering a panel of CD3 antibodies for use in precision cancer treatments,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “With our strong cash position and book of business, we also continued pursuing deal structures that allow us to capture more downstream value and expanded an existing partnership to include the option to co-develop therapeutic programs.”

Q1 2022 Business Summary

● Earned $317 million in total revenue.

● Generated net earnings of $169 million, compared to $117 million in Q1 2021.

● Added two programs under contract with an existing partner, resulting in a cumulative total of 158 programs under contract with 36 different partners.

● Started discovery on six programs, bringing the cumulative number of program starts to 84.

● Confirmed one new molecule advanced into the clinic, bringing the cumulative total to six.

1

Key Business Metrics

Cumulative Metrics	March 31, 2021		March 31, 2022		Change %
Number of discovery partners		29		36		24	%
Programs under contract		119		158		33	%
Program starts		54		84		56	%
Molecules in the clinic		1		6		500	%

AbCellera added two discovery programs in Q1 to reach a cumulative total of 158 discovery programs as of March 31, 2022 (up from 119 on March 31, 2021), that are either completed, in progress, or under contract with 36 different partners (up from 29 on March 31, 2021). AbCellera started discovery on an additional six programs in Q1 to reach a cumulative total of 84 program starts (up from 54 on March 31, 2021). AbCellera’s partners advanced one additional molecule into the clinic in Q1 2022, bringing the cumulative total to six.

Discussion of Q1 2022 Financial Results

● Revenue – Total revenue was$316.6 million, compared to $202.7 million in Q1 2021. Royalties associated with bamlanivimab and bebtelovimab were $307.0 million. The partnership business produced research fees of $9.3 million, compared to $4.0 million in Q1 2021. Licensing revenue was $0.2 million.

● Research & Development (R&D) Expenses – R&D expenses were $26.4 million, compared to $12.4 million in Q1 2021, reflecting continuing investments in the capacity and capabilities of AbCellera’s discovery and development platform.

● Sales & Marketing (S&M) Expenses – S&M expenses were $2.4 million, compared to $2.6 million in Q1 2021.

● General & Administrative (G&A) Expenses – G&A expenses were $14.3 million, compared to $6.4 million in Q1 2021, with the increase driven by investments to support the growth of the company and non-cash stock-based compensation.

● Net Earnings – Net earnings were $168.6 million, or $0.59 per share on a basic and $0.54 on a diluted basis compared to $117.2 million, or $0.43 per share on a basic and $0.37 on a diluted basis in Q1 2021.

● Liquidity – $786.1 million of cash, cash equivalents, and marketable securities.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.

2

AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Definition of Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

Number of discovery partnersrepresents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract.

Programs under contractrepresent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

AbCellera Forward-looking Statements

3

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Source: AbCellera Biologics Inc.

Inquiries

Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236) 521-6774
Business Development: Neil Berkley; bd@abcellera.com, +1(604) 559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778) 729-9116

4

AbCellera Biologics Inc.

Condensed Consolidated Statements of Income and

Comprehensive Income

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data)

(Unaudited)

	Three months ended March 31,
	2021			2022
Revenue:
Research fees	$	3,986		$	9,333
Licensing revenue		20,259			231
Milestone payments		7,000			-
Royalty revenue		171,496			307,017
Total revenue		202,741			316,581
Operating expenses:
Royalty fees		20,010			44,637
Research and development(1)		12,352			26,366
Sales and marketing(1)		2,578			2,370
General and administrative(1)		6,422			14,268
Depreciation and amortization		3,305			3,990
Total operating expenses		44,667			91,631
Income from operations		158,074			224,950
Other (income)
Other income		(265	)		(665	)
Grants and incentives		(3,148	)		(5,194	)
Total other (income)		(3,413	)		(5,859	)
Net earnings before income tax		161,487			230,809
Income tax expense		44,266			62,236
Net earnings	$	117,221		$	168,573
Foreign currency translation adjustment		-			507
Comprehensive income	$	117,221		$	169,080
Net earnings per share attributable to common shareholders
Basic	$	0.43		$	0.59
Diluted	$	0.37		$	0.54
Weighted-average common shares outstanding
Basic		269,697,212			283,895,020
Diluted		320,282,747			311,482,017

¹ Exclusive of depreciation and amortization

5

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheet

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

(Unaudited)

	December 31, 2021		March 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	476,142	$	545,718
Marketable securities		246,835		240,335
Total cash, cash equivalents, and marketable securities		722,977		786,053
Accounts and accrued receivable		160,576		334,403
Restricted cash		25,000		25,000
Other current assets		21,247		28,922
Total current assets		929,800		1,174,378
Long-term assets:
Property and equipment, net		111,616		122,049
Intangible assets, net		148,392		145,785
Goodwill		47,806		47,806
Investments in and loans to equity accounted investees		50,313		58,882
Other long-term assets		30,642		43,389
Total long-term assets		388,769		417,911
Total assets	$	1,318,569	$	1,592,289
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other liabilities	$	32,017	$	25,717
Current portion of contingent consideration payable		22,934		27,499
Income taxes payable		35,683		105,648
Accrued royalties payable		22,506		45,364
Deferred revenue		7,536		9,190
Total current liabilities		120,676		213,418
Long-term liabilities:
Operating lease liability		36,413		36,356
Deferred revenue and grant funding		60,758		64,151
Contingent consideration payable		35,886		30,623
Deferred tax liability		37,370		36,804
Other long-term liabilities		1,733		3,430
Total long-term liabilities		172,160		171,364
Total liabilities		292,836		384,782
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2021 and March 31, 2022: 283,257,104 and 284,521,181 shares issued and outstanding at December 31, 2021 and March 31, 2022, respectively		722,430		725,755
Additional paid-in capital		35,357		44,726
Accumulated other comprehensive income		280		787
Accumulated earnings		267,666		436,239
Total shareholders' equity		1,025,733		1,207,507
Total liabilities and shareholders' equity	$	1,318,569	$	1,592,289

6

AbCellera Biologics Inc.

Condensed Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. dollars)

(Unaudited)

	Three months ended March 31,
	2021			2022
Cash flows from operating activities:
Net income	$	117,221		$	168,573
Cash flows from operating activities:
Depreciation of property and equipment		840			1,391
Amortization of intangible assets		2,465			2,606
Amortization of operating lease right-of-use assets		661			976
Stock-based compensation		5,427			12,291
Other		432			(592	)
Changes in operating assets and liabilities:
Accounts and accrued research fees receivable		(30,073	)		(8,751	)
Accrued royalties receivable		26,861			(167,914	)
Income taxes payable		(6,123	)		69,965
Accounts payable and accrued liabilities		(5,194	)		751
Deferred revenue		6,086			941
Accrued royalties payable		(7,134	)		22,857
Deferred grant revenue		2,468			4,682
Other assets		(4,392	)		(7,557	)
Net cash provided by operating activities		109,545			100,219
Cash flows from investing activities:
Purchases of property and equipment		(3,644	)		(14,495	)
Purchase of marketable securities		-			(51,774	)
Proceeds from marketable securities		-			57,294
Receipt of grant funding		-			2,596
Long-term investments and other assets		-			(11,657	)
Investment in and loans to equity accounted investees		(12,195	)		(8,335	)
Net cash used in investing activities		(15,839	)		(26,371	)
Cash flows from financing activities:
Repayment of long-term debt and contingent consideration		(1,716	)		(72	)
Proceeds from long-term debt and issuance of common shares pursuant to exercise of stock options		173			1,941
Payment of liability for in-licensing agreement		-			(5,000	)
Net cash provided by (used in) financing activities		(1,543	)		(3,131	)
Effect of exchange rate changes on cash and cash equivalents		(484	)		(204	)
Increase in cash and cash equivalents		91,679			70,513
Cash and cash equivalents and restricted cash, beginning of period		594,116			501,142
Cash and cash equivalents and restricted cash, end of period	$	685,795		$	571,655
Restricted cash included in other long-term assets		-			(937	)
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$	685,795		$	570,718
Supplemental disclosure of non-cash investing and financing activities
Property plant and equipment in accounts payable		423			2,353
Right-of-use assets obtained in exchange for operating lease obligation		14,188			658

7

EX-99.2

Exhibit 99.2 Exhibit 99.2 AbCellera Q1 2022 BUSINESS UPDATE MAY 10, 2022 COPYRIGHT © ABCELLERA

2 DISCLAIMER This presentation contains forward- looking statements including statement made pursuant to the safe harbor provisions of the private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend”, “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may no prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.01 2022 BUSINESS UPDATE COPYRIGHT ABCELLERA COPYRIGHT © ABCELLERA

STRONG RESUTS & FOCUS ON KEY PRIORITIES 01 2022 BUSINESS UPDATE SUMMARY NEW programs under contract 6 NEW programs started 1 MOLECULE entered the clinic 158 cumulative programs under contract 84 cumulative programs started >$780M in cash, cash equivalents & marketable securities

The best capabilities in the world from target to Ind Ind engine 2x faster solve the unsolvable Highest quality Unprecedented scale Composition of matter Patentable DNA sequence of the drug Drug substance GMP material for clinical testing Technology software+data science workforce infrastructure Targets specifications Q1 2022 business update 4 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE

Deal structures that capture downstream value we expanded our existing partnership with empirico to 7 targets, and the new agreement provides us with the option, on a program-by- program basis, to co-invest in preclinical and clinical development in exchange for a greater ownership stake in the program. In the event we continue to co-invest, we will maintain a 50% interest in each program. Empirico a next generation therapeutics company targets multi-year multiple indications 7 q1 2022 business update 5 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE

A diverse panel of cd3 antibodies to create new cancer therapies we used our technology to find hundreds of cd3-binding antibodies that can be combine to create precision cancer therapies. We then used our clinically-validated bispecifics platform, orthomab tm to pair the cd3-binding antibodies with a single EGFR binding arm and confirm their function. Diverse developable validated Q1 2022 business update technology development: t cell engager platform CD3-binding antibodies 6 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE

Strong portfolio growth. Cumulative # of Program Starts Cumulative # of Molecules in the clicnic Total # of Programs Under Contract 158 Total # of Discovery Partners 36 84 90 80 70 60 50 40 30 20 10 0 84 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 6 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 0 1 2 3 4 5 6 - WITHOUT downstream participation + WITH downstream participation Note Showing year – end figures except for most recent quarters. Histrorical results are not necessarily indicative of future results. COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE Q1 2022 BUSINESS UPDATE FINANCIALS 8

9 Q12022 BUSINESS UPDATE 6 molecule in the clinic,2 authorized for emergency use. MOLECULE STAGE PARTNER THERAPEUTIC AREA PROGRAM TYPE bamanivimab (LY Cov555) Marketed Emergency Use Authorization (EUA) lilly infectious disease Covid 19 Abcellera Discovery partnership bebtelovimab (LY-CoV1404) Marketed, Emergency Use Authorization (EUA) lilly infectious disease-COVID-19 NBL-012 Phase I NovaRock dermatology gastrointestinal disease immunology NBL- 015 INB approved oncology undisclosed IND approved undisclosed undisclosed IVX-01 Clinical field study animal health AbCellera Discovery Partnership As of March 31, 2022 COPYRIGHT © ABCELLERA As of March 31, 2022

$316.5M total revenue, driven by royalties for bamlanivimab and bebtelovimab. Revenue USD 316.5M ROYALTIES MILESTONES LICENSING RESEARCH FEES $202.8M $171.5M $7.0M $4.0M $20.3M Q1 2021 $307.0M $9.3M $0.2M Q1 2021 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE 10

Q1 2022 BUSINESS UPDATE Operating expenses reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT +$14.0M $12.4M Q1 2021 $26.4M Q1 2022 SALES & MARKETING -$0.2M $2.5M Q1 2021 $2.4M Q1 2022 GENERAL & ADMIN +$7.8M $6.5M Q1 2021 $14.3M Q1 2022 11 COPYRIGHT © ABCELLERA FINANCIALS

12 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE FINANCIALS Net earning of $168.6M: equivalent to 0.59 (basic) and 0.54 (diluted) per share. Earning USD NET EARNINGS EARNING PER SHARE: BASIC EARNING PER SHARE: DILUTED $117.1M Q1 2021 $168.6M Q1 2022 $0.43 2021 Q1 $0.59 2022 Q1 $0.37 2021 Q1 $0.54 2022 Q1

Over $780 million in total cash, equivalents, and marketable securities Cash Flows USD Q1 2022 BUSINESS UPDATE $748M $247M $476M $25M $100M [$26M] [$3M] $0M $812M $240M Marketable $547M Cash&Equivalents $25M Restricted Cash 23-Dec-21 OPERATING INVESTING FINANCING FX 31-MAR-22 13 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE FINANCIALS

Q1 2022 BUSINESS UDPATE COPYRIGHT © ABCELLERA 14 THANK YOU

XML

Document and Entity Information	May 10, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 10, 2022
Entity Registrant Name	ABCELLERA BIOLOGICS INC.
Entity Central Index Key	0001703057
Entity Incorporation, State or Country Code	A1
Entity File Number	001-39781
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	2215 Yukon Street
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V5Y 0A1
City Area Code	604
Local Phone Number	559-9005
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common shares
Trading Symbol	ABCL
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false